Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
about
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinTrabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesPrinciples in Management of Soft Tissue SarcomaCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasUK guidelines for the management of soft tissue sarcomasTrabectedin in soft tissue sarcomasAdvances and controversies in the management of soft tissue sarcomas.Emerging therapies for adult soft tissue sarcoma.Recent advances in understanding and managing leiomyosarcomasA comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective StudyPatterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.Recent advances in the management of liposarcoma.Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomasTargeted therapy for soft tissue sarcomas in adolescents and young adults.Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial resultsCurrent management options for liposarcoma and challenges for the future.Trabectedin: novel insights in the treatment of advanced sarcoma.Going further in the knowledge of Yondelis®; what's new in daily clinical practice?Soft tissue sarcomas, a look into the future: different treatments for different subtypes.Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.Review of past and present clinical cases with a view to future treatment options.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Trabectedin for advanced soft tissue sarcomas: a single institution experience.Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.Oncological outcomes of laparoscopic surgery of liver metastases: a single-centre experience.Managing sarcoma: where have we come from and where are we going?Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
P2860
Q26738346-83D2ED23-E73F-4D9A-89A1-993A229B0344Q26745502-D5B56FD1-11C1-4F4A-A4AB-D6D3E7311658Q26795619-CA302144-C1EF-46D9-8F6A-C1F6B5E4070CQ28076210-B7CD3745-6460-490B-8112-C2A20167AF68Q28076730-D66A8968-4395-46D1-8768-B866883AE059Q28085505-CD946566-85B9-4B0D-A8A4-18FB7825E721Q30240228-777C6A14-9025-4036-8FA2-08BD2F4D8E26Q34659806-43F647EF-D6ED-45AF-A890-21ADD519F47AQ34670825-ECBBE246-EB63-4DA9-83C6-8A991770176DQ35246995-C702C070-4D7E-46B1-8C28-3D0779A28B76Q35738934-8C5DEB46-2893-48E5-AB30-D77B49987EE1Q35898258-24AFE3C8-6062-4D78-84C0-48EEEEEF4E02Q35909766-BF8A2394-543D-41A1-93DC-AC9E801CC04AQ36341242-4BF25ACF-8BFF-43A5-A5D7-632547EF604BQ36530034-7D76AE1C-B263-4C1A-AFCB-A8C593208A30Q36707444-0B4ADD3C-2538-4985-8893-1034D5E3A968Q37402813-9F3FDCF2-2EDC-476F-BF7B-2D04CA6E5661Q37577681-E15AEB2D-7CBE-4729-B497-2FD9355873EDQ37616621-2F843F31-421C-40FD-8D1E-1121AD89BD93Q37669484-05478281-C4B1-4C04-A396-DC52C51AB225Q37742014-EE15617F-DD6C-4790-A090-7A5BB3FF85D8Q38128352-FA020651-1C06-4DE1-B43B-126555BF79CAQ38161734-A58DF762-2D1E-4ADD-BDB6-4599B6AFC4ACQ38176387-26A561FC-AD3D-43C7-A597-FA4621B21A4BQ38206396-D5F92E1C-15BC-40AA-9A4B-1BD6B73759A5Q38232372-D6F906B3-056A-453A-B9B9-FA15F73CE04CQ38232373-5A69C090-23EA-47F7-BE7F-3841350CE778Q38515911-88EBCF4F-81EB-42DC-9BCD-C9C04BAA74A3Q38688923-1BA3190D-5B44-4363-92D2-643E187ED2B5Q38731757-DBE1BED1-BE30-452D-BFA1-8D5072900DE4Q38789729-B2FF719C-03BE-403F-99DB-AC7042CE0064Q38797843-356AFDE1-9E2F-45C4-BE6D-B918FEBAEDF0Q39267079-0B327216-F793-4D0A-9CFA-0D55623BB26AQ39359343-E70B366D-AD6E-42AA-9661-423AEB027206Q39454037-46E20410-5DE9-43DE-A1D0-0B97EB1BE808Q41008543-AF5D2300-89ED-4D4E-A5D2-43D34BC40FDBQ41643586-79C0205F-1A76-4844-A475-0032BD61DB31Q41988197-CE02CED3-4829-4C98-B779-BB70B36BB4AFQ42195995-064354D3-A12E-40DC-80CB-3817254141B8Q44301485-8AE7E97B-858D-4443-AFFC-2081A58F59C4
P2860
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical outcomes and safety w ...... expanded access program study.
@ast
Clinical outcomes and safety w ...... expanded access program study.
@en
Clinical outcomes and safety w ...... expanded access program study.
@nl
type
label
Clinical outcomes and safety w ...... expanded access program study.
@ast
Clinical outcomes and safety w ...... expanded access program study.
@en
Clinical outcomes and safety w ...... expanded access program study.
@nl
prefLabel
Clinical outcomes and safety w ...... expanded access program study.
@ast
Clinical outcomes and safety w ...... expanded access program study.
@en
Clinical outcomes and safety w ...... expanded access program study.
@nl
P2093
P2860
P356
P1433
P1476
Clinical outcomes and safety w ...... expanded access program study.
@en
P2093
B L Samuels
G D Demetri
M von Mehren
P E Kaiser
S Schuetze
P2860
P304
P356
10.1093/ANNONC/MDS659
P577
2013-02-05T00:00:00Z